{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T10:39:47Z","timestamp":1777977587186,"version":"3.51.4"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"iMM-CARE"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-025-00901-0","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T18:11:02Z","timestamp":1746555062000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Immunotherapy in lung cancer brain metastases"],"prefix":"10.1038","volume":"9","author":[{"given":"Eunice","family":"Paisana","sequence":"first","affiliation":[]},{"given":"Rita","family":"Casc\u00e3o","sequence":"additional","affiliation":[]},{"given":"Magda","family":"Alvoeiro","sequence":"additional","affiliation":[]},{"given":"Francisco","family":"F\u00e9lix","sequence":"additional","affiliation":[]},{"given":"Guilherme","family":"Martins","sequence":"additional","affiliation":[]},{"given":"Carla","family":"Guerreiro","sequence":"additional","affiliation":[]},{"given":"Rafael","family":"Roque","sequence":"additional","affiliation":[]},{"given":"Rafael","family":"Cruz","sequence":"additional","affiliation":[]},{"given":"Teresa R.","family":"Pacheco","sequence":"additional","affiliation":[]},{"given":"Ana Cristina","family":"Amado","sequence":"additional","affiliation":[]},{"given":"Filipa","family":"Ferro","sequence":"additional","affiliation":[]},{"given":"Andrea","family":"Lopes Machado","sequence":"additional","affiliation":[]},{"given":"Ana Sofia","family":"Vilari\u00e7a","sequence":"additional","affiliation":[]},{"given":"Direndra","family":"Hasmucrai","sequence":"additional","affiliation":[]},{"given":"Paula","family":"Alves","sequence":"additional","affiliation":[]},{"given":"Claudia C.","family":"Faria","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"key":"901_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"901_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41572-018-0055-y","volume":"5","author":"AS Achrol","year":"2019","unstructured":"Achrol, A. S. et al. Brain metastases. Nat. Rev. Dis. Prim. 5, 5 (2019).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"901_CR3","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","volume":"22","author":"JS Barnholtz-Sloan","year":"2004","unstructured":"Barnholtz-Sloan, J. S. et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J. Clin. Oncol. 22, 2865\u20132872 (2004).","journal-title":"J. Clin. Oncol."},{"key":"901_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2015-000024","volume":"1","author":"AS Berghoff","year":"2016","unstructured":"Berghoff, A. S. et al. Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers. ESMO Open 1, e000024 (2016).","journal-title":"ESMO Open"},{"key":"901_CR5","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1097\/CCO.0000000000000573","volume":"31","author":"N Rosenfelder","year":"2019","unstructured":"Rosenfelder, N. & Brada, M. Integrated treatment of brain metastases. Curr. Opin. Oncol. 31, 501\u2013507 (2019).","journal-title":"Curr. Opin. Oncol."},{"key":"901_CR6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41571-019-0320-3","volume":"17","author":"JH Suh","year":"2020","unstructured":"Suh, J. H. et al. Current approaches to the management of brain metastases. Nat. Rev. Clin. Oncol. 17, 279\u2013299 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"901_CR7","doi-asserted-by":"publisher","first-page":"6748","DOI":"10.3390\/ijms23126748","volume":"23","author":"A Michelotti","year":"2022","unstructured":"Michelotti, A. et al. NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease. Int. J. Mol. Sci. 23, 6748 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"901_CR8","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","volume":"88","author":"D Rangachari","year":"2015","unstructured":"Rangachari, D. et al. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer 88, 108\u2013111 (2015).","journal-title":"Lung Cancer"},{"key":"901_CR9","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","volume":"80","author":"IA Prior","year":"2020","unstructured":"Prior, I. A., Hood, F. E. & Hartley, J. L. The Frequency of Ras Mutations in Cancer. Cancer Res. 80, 2969\u20132974 (2020).","journal-title":"Cancer Res."},{"key":"901_CR10","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1158\/1078-0432.CCR-22-0383","volume":"28","author":"JK Sabari","year":"2022","unstructured":"Sabari, J. K. et al. Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer. Clin. Cancer Res 28, 3318\u20133328 (2022).","journal-title":"Clin. Cancer Res"},{"key":"901_CR11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1227\/neu.0000000000002372","volume":"93","author":"A Berger","year":"2023","unstructured":"Berger, A. et al. Extended Survival in Patients With Non-Small-Cell Lung Cancer-Associated Brain Metastases in the Modern Era. Neurosurgery 93, 50\u201359 (2023).","journal-title":"Neurosurgery"},{"key":"901_CR12","doi-asserted-by":"publisher","first-page":"6961","DOI":"10.3390\/ijms25136961","volume":"25","author":"C Boldig","year":"2024","unstructured":"Boldig, C., Boldig, K., Mokhtari, S. & Etame, A. B. A Review of the Molecular Determinants of Therapeutic Response in Non-Small Cell Lung Cancer Brain Metastases. Int. J. Mol. Sci. 25, 6961 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"901_CR13","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1200\/JCO.2018.77.9363","volume":"36","author":"YL Wu","year":"2018","unstructured":"Wu, Y. L. et al. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). J. Clin. Oncol. 36, 2702\u20132709 (2018).","journal-title":"J. Clin. Oncol."},{"key":"901_CR14","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1200\/JCO.23.02219","volume":"42","author":"PA Janne","year":"2024","unstructured":"Janne, P. A. et al. CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer. J. Clin. Oncol. 42, 808\u2013820 (2024).","journal-title":"J. Clin. Oncol."},{"key":"901_CR15","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1200\/JCO.2016.68.4639","volume":"34","author":"SM Gadgeel","year":"2016","unstructured":"Gadgeel, S. M. et al. Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer. J. Clin. Oncol. 34, 4079\u20134085 (2016).","journal-title":"J. Clin. Oncol."},{"key":"901_CR16","doi-asserted-by":"publisher","first-page":"379","DOI":"10.21037\/tlcr-22-638","volume":"12","author":"TA Nelson","year":"2023","unstructured":"Nelson, T. A. & Wang, N. Targeting lung cancer brain metastases: a narrative review of emerging insights for anaplastic lymphoma kinase (ALK)-positive disease. Transl. Lung Cancer Res. 12, 379\u2013392 (2023).","journal-title":"Transl. Lung Cancer Res."},{"key":"901_CR17","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1200\/JCO.21.02314","volume":"40","author":"MA Vogelbaum","year":"2022","unstructured":"Vogelbaum, M. A. et al. Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. J. Clin. Oncol. 40, 492\u2013516 (2022).","journal-title":"J. Clin. Oncol."},{"key":"901_CR18","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1093\/neuonc\/noab101","volume":"23","author":"N Lamba","year":"2021","unstructured":"Lamba, N., Wen, P. Y. & Aizer, A. A. Epidemiology of brain metastases and leptomeningeal disease. Neuro Oncol. 23, 1447\u20131456 (2021).","journal-title":"Neuro Oncol."},{"key":"901_CR19","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41392-022-01168-8","volume":"7","author":"Y Yang","year":"2022","unstructured":"Yang, Y. et al. Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. Signal Transduct. Target Ther. 7, 329 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"901_CR20","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.annonc.2021.07.016","volume":"32","author":"E Le Rhun","year":"2021","unstructured":"Le Rhun, E. et al. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. Ann. Oncol. 32, 1332\u20131347 (2021).","journal-title":"Ann. Oncol."},{"key":"901_CR21","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.3389\/fimmu.2019.01713","volume":"10","author":"M Schulz","year":"2019","unstructured":"Schulz, M. et al. Microenvironmental Regulation of Tumor Progression and Therapeutic Response in Brain Metastasis. Front Immunol. 10, 1713 (2019).","journal-title":"Front Immunol."},{"key":"901_CR22","doi-asserted-by":"publisher","first-page":"4546","DOI":"10.1016\/j.cell.2023.08.043","volume":"186","author":"RR Maas","year":"2023","unstructured":"Maas, R. R. et al. The local microenvironment drives activation of neutrophils in human brain tumors. Cell 186, 4546\u20134566.e4527 (2023).","journal-title":"Cell"},{"key":"901_CR23","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.ccell.2023.12.018","volume":"42","author":"L Bejarano","year":"2024","unstructured":"Bejarano, L. et al. Interrogation of endothelial and mural cells in brain metastasis reveals key immune-regulatory mechanisms. Cancer Cell 42, 378\u2013395.e310 (2024).","journal-title":"Cancer Cell"},{"key":"901_CR24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.cell.2016.02.025","volume":"165","author":"S Malladi","year":"2016","unstructured":"Malladi, S. et al. Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT. Cell 165, 45\u201360 (2016).","journal-title":"Cell"},{"key":"901_CR25","doi-asserted-by":"publisher","first-page":"e1057388","DOI":"10.1080\/2162402X.2015.1057388","volume":"5","author":"AS Berghoff","year":"2016","unstructured":"Berghoff, A. S. et al. Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. Oncoimmunology 5, e1057388 (2016).","journal-title":"Oncoimmunology"},{"key":"901_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0306220","volume":"19","author":"SF Sajjadi","year":"2024","unstructured":"Sajjadi, S. F., Salehi, N. & Sadeghi, M. Comprehensive integrated single-cell RNA sequencing analysis of brain metastasis and glioma microenvironment: Contrasting heterogeneity landscapes. PLoS One 19, e0306220 (2024).","journal-title":"PLoS One"},{"key":"901_CR27","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1093\/annonc\/mdz207","volume":"30","author":"Y Kudo","year":"2019","unstructured":"Kudo, Y. et al. Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer. Ann. Oncol. 30, 1521\u20131530 (2019).","journal-title":"Ann. Oncol."},{"key":"901_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100900","volume":"4","author":"AF Alvarez-Prado","year":"2023","unstructured":"Alvarez-Prado, A. F. et al. Immunogenomic analysis of human brain metastases reveals diverse immune landscapes across genetically distinct tumors. Cell Rep. Med. 4, 100900 (2023).","journal-title":"Cell Rep. Med."},{"key":"901_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114613","volume":"43","author":"YS Li","year":"2024","unstructured":"Li, Y. S. et al. Lipid-associated macrophages for osimertinib resistance and leptomeningeal metastases in NSCLC. Cell Rep. 43, 114613 (2024).","journal-title":"Cell Rep."},{"key":"901_CR30","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/neuonc\/noae219","volume":"27","author":"LD Schreurs","year":"2025","unstructured":"Schreurs, L. D. et al. The immune landscape in brain metastasis. Neuro Oncol. 27, 50\u201362 (2025).","journal-title":"Neuro Oncol."},{"key":"901_CR31","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1038\/s41591-018-0044-4","volume":"24","author":"N Priego","year":"2018","unstructured":"Priego, N. et al. STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis. Nat. Med. 24, 1024\u20131035 (2018).","journal-title":"Nat. Med."},{"key":"901_CR32","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.cell.2020.07.013","volume":"182","author":"M Molgora","year":"2020","unstructured":"Molgora, M. et al. TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy. Cell 182, 886\u2013900.e817 (2020).","journal-title":"Cell"},{"key":"901_CR33","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1158\/0008-5472.CAN-20-3510","volume":"81","author":"S Tartey","year":"2021","unstructured":"Tartey, S. et al. A MyD88\/IL1R Axis Regulates PD-1 Expression on Tumor-Associated Macrophages and Sustains Their Immunosuppressive Function in Melanoma. Cancer Res. 81, 2358\u20132372 (2021).","journal-title":"Cancer Res."},{"key":"901_CR34","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s43018-023-00566-3","volume":"4","author":"V Wischnewski","year":"2023","unstructured":"Wischnewski, V. et al. Phenotypic diversity of T cells in human primary and metastatic brain tumors revealed by multiomic interrogation. Nat. Cancer 4, 908\u2013924 (2023).","journal-title":"Nat. Cancer"},{"key":"901_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16164-1","volume":"11","author":"N Kim","year":"2020","unstructured":"Kim, N. et al. Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. Nat. Commun. 11, 2285 (2020).","journal-title":"Nat. Commun."},{"key":"901_CR36","doi-asserted-by":"publisher","first-page":"101054","DOI":"10.1016\/j.xcrm.2023.101054","volume":"4","author":"WH Hudson","year":"2023","unstructured":"Hudson, W. H., Olson, J. J. & Sudmeier, L. J. Immune microenvironment remodeling after radiation of a progressing brain metastasis. Cell Rep. Med. 4, 101054 (2023).","journal-title":"Cell Rep. Med."},{"key":"901_CR37","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","volume":"17","author":"SB Goldberg","year":"2016","unstructured":"Goldberg, S. B. et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 17, 976\u2013983 (2016).","journal-title":"Lancet Oncol."},{"key":"901_CR38","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1016\/S1556-0864(23)00298-8","volume":"18","author":"ALOO Granados","year":"2023","unstructured":"Granados, A. L. O. O. et al. 44P Dostarlimab (Dos) or pembrolizumab (Pem) + chemotherapy (CT) in previously untreated metastatic non-squamous non-small cell lung cancer (NSCLC): Patient (Pt) and disease characteristics subgroup analyses from the PERLA trial. J. Thorac. Oncol. 18, S67\u2013S68 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"901_CR39","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1200\/JCO.19.03136","volume":"38","author":"S Gadgeel","year":"2020","unstructured":"Gadgeel, S. et al. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J. Clin. Oncol. 38, 1505\u20131517 (2020).","journal-title":"J. Clin. Oncol."},{"key":"901_CR40","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.jtho.2024.04.011","volume":"19","author":"SM Gadgeel","year":"2024","unstructured":"Gadgeel, S. M. et al. Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up. J. Thorac. Oncol. 19, 1228\u20131241 (2024).","journal-title":"J. Thorac. Oncol."},{"key":"901_CR41","doi-asserted-by":"publisher","first-page":"4478","DOI":"10.1200\/JCO.22.02561","volume":"41","author":"E Nadal","year":"2023","unstructured":"Nadal, E. et al. Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non\u2013Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17\/05). J. Clin. Oncol. 41, 4478\u20134485 (2023).","journal-title":"J. Clin. Oncol."},{"key":"901_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.875488","volume":"13","author":"X Chu","year":"2022","unstructured":"Chu, X. et al. The Long-Term and Short-Term Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis. Front Immunol. 13, 875488 (2022).","journal-title":"Front Immunol."},{"key":"901_CR43","volume":"5","author":"P Wong","year":"2023","unstructured":"Wong, P. et al. Phase II multicenter trial combining nivolumab and radiosurgery for NSCLC and RCC brain metastases. Neurooncol Adv. 5, vdad018 (2023).","journal-title":"Neurooncol Adv."},{"key":"901_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109601","volume":"27","author":"JM Shireman","year":"2024","unstructured":"Shireman, J. M. et al. Genomic analysis of human brain metastases treated with stereotactic radiosurgery reveals unique signature based on treatment failure. iScience 27, 109601 (2024).","journal-title":"iScience"},{"key":"901_CR45","volume":"2","author":"AS Mansfield","year":"2021","unstructured":"Mansfield, A. S. et al. Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1-Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042. JTO Clin. Res Rep. 2, 100205 (2021).","journal-title":"JTO Clin. Res Rep."},{"key":"901_CR46","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/s41591-020-0918-0","volume":"26","author":"PK Brastianos","year":"2020","unstructured":"Brastianos, P. K. et al. Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat. Med 26, 1280\u20131284 (2020).","journal-title":"Nat. Med"},{"key":"901_CR47","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1038\/s41591-023-02392-7","volume":"29","author":"PK Brastianos","year":"2023","unstructured":"Brastianos, P. K. et al. Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results. Nat. Med. 29, 1728\u20131737 (2023).","journal-title":"Nat. Med."},{"key":"901_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25859-y","volume":"12","author":"PK Brastianos","year":"2021","unstructured":"Brastianos, P. K. et al. Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis. Nat. Commun. 12, 5954 (2021).","journal-title":"Nat. Commun."},{"key":"901_CR49","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ejca.2021.03.037","volume":"150","author":"MM Zheng","year":"2021","unstructured":"Zheng, M. M. et al. Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments. Eur. J. Cancer 150, 23\u201330 (2021).","journal-title":"Eur. J. Cancer"},{"key":"901_CR50","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1200\/JCO.2024.42.16_suppl.2034","volume":"42","author":"E Adib","year":"2024","unstructured":"Adib, E., Nassar, A., Kwiatkowski, D. J. & Aizer, A. PD-L1, tumor mutational burden (TMB) and long-term survival in patients with non-small cell lung cancer (NSCLC) and brain metastases. J. Clin. Oncol. 42, 2034\u20132034 (2024).","journal-title":"J. Clin. Oncol."},{"key":"901_CR51","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","volume":"21","author":"SB Goldberg","year":"2020","unstructured":"Goldberg, S. B. et al. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol. 21, 655\u2013663 (2020).","journal-title":"Lancet Oncol."},{"key":"901_CR52","doi-asserted-by":"publisher","first-page":"S845","DOI":"10.1016\/j.annonc.2024.08.1387","volume":"35","author":"T Iuchi","year":"2024","unstructured":"Iuchi, T. et al. 1332P Effects of immune checkpoint inhibitors for EGFR-wild\/ALK-negative NSCLC patients with untreated brain metastases. Ann. Oncol. 35, S845\u2013S846 (2024).","journal-title":"Ann. Oncol."},{"key":"901_CR53","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.jtho.2023.04.021","volume":"18","author":"M Reck","year":"2023","unstructured":"Reck, M. et al. Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1. J. Thorac. Oncol. 18, 1055\u20131069 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"901_CR54","doi-asserted-by":"publisher","first-page":"101242","DOI":"10.1016\/j.xcrm.2023.101242","volume":"4","author":"S Frentzas","year":"2023","unstructured":"Frentzas, S. et al. A phase 1a\/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors. Cell Rep. Med. 4, 101242 (2023).","journal-title":"Cell Rep. Med."},{"key":"901_CR55","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S1470-2045(24)00643-0","volume":"26","author":"Y Xu","year":"2025","unstructured":"Xu, Y. et al. Brain radiotherapy combined with camrelizumab and platinum-doublet chemotherapy for previously untreated advanced non-small-cell lung cancer with brain metastases (C-Brain): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 26, 74\u201384 (2025).","journal-title":"Lancet Oncol."},{"key":"901_CR56","doi-asserted-by":"crossref","unstructured":"Li, Y. S. et al. First-Line Camrelizumab versus Placebo Plus Chemotherapy with or without Radiotherapy for Brain Metastases in Non-Small-Cell Lung Cancer: The CTONG 2003 Randomized Placebo-Controlled Trial. J. Thorac. Oncol. (2025).","DOI":"10.1016\/j.jtho.2025.02.004"},{"key":"901_CR57","doi-asserted-by":"publisher","first-page":"269","DOI":"10.21037\/tlcr-23-687","volume":"13","author":"S Zhao","year":"2024","unstructured":"Zhao, S. et al. Intracranial response pattern, tolerability and biomarkers associated with brain metastases in non-small cell lung cancer treated by tislelizumab plus chemotherapy. Transl. Lung Cancer Res. 13, 269\u2013279 (2024).","journal-title":"Transl. Lung Cancer Res."},{"key":"901_CR58","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/s41591-024-02808-y","volume":"30","author":"B Besse","year":"2024","unstructured":"Besse, B. et al. Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial. Nat. Med. 30, 716\u2013729 (2024).","journal-title":"Nat. Med."},{"key":"901_CR59","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jtho.2021.09.014","volume":"17","author":"N Nogami","year":"2022","unstructured":"Nogami, N. et al. IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain. J. Thorac. Oncol. 17, 309\u2013323 (2022).","journal-title":"J. Thorac. Oncol."},{"key":"901_CR60","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s00262-023-03599-w","volume":"73","author":"KE Blethen","year":"2024","unstructured":"Blethen, K. E. et al. Coordination of anti-CTLA-4 with whole-brain radiation therapy decreases tumor burden during treatment in a novel syngeneic model of lung cancer brain metastasis. Cancer Immunol. Immunother. 73, 20 (2024).","journal-title":"Cancer Immunol. Immunother."},{"key":"901_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101533","volume":"5","author":"L Wang","year":"2024","unstructured":"Wang, L. et al. Targeting the HSP47-collagen axis inhibits brain metastasis by reversing M2 microglial polarization and restoring anti-tumor immunity. Cell Rep. Med. 5, 101533 (2024).","journal-title":"Cell Rep. Med."},{"key":"901_CR62","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2163781","volume":"12","author":"T Xu","year":"2023","unstructured":"Xu, T. et al. In vivo dynamics and anti-tumor effects of EpCAM-directed CAR T-cells against brain metastases from lung cancer. Oncoimmunology 12, 2163781 (2023).","journal-title":"Oncoimmunology"},{"key":"901_CR63","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1158\/1078-0432.CCR-23-1735","volume":"30","author":"AM Kieliszek","year":"2024","unstructured":"Kieliszek, A. M. et al. Intratumoral Delivery of Chimeric Antigen Receptor T Cells Targeting CD133 Effectively Treats Brain Metastases. Clin. Cancer Res. 30, 554\u2013563 (2024).","journal-title":"Clin. Cancer Res."},{"key":"901_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29647-0","volume":"13","author":"H Li","year":"2022","unstructured":"Li, H. et al. Targeting brain lesions of non-small cell lung cancer by enhancing CCL2-mediated CAR-T cell migration. Nat. Commun. 13, 2154 (2022).","journal-title":"Nat. Commun."},{"key":"901_CR65","doi-asserted-by":"publisher","first-page":"101777","DOI":"10.1016\/j.xcrm.2024.101777","volume":"5","author":"Y Liu","year":"2024","unstructured":"Liu, Y. et al. Modeling lung adenocarcinoma metastases using patient-derived organoids. Cell Rep. Med. 5, 101777 (2024).","journal-title":"Cell Rep. Med."},{"key":"901_CR66","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","volume":"20","author":"AJ Hou","year":"2021","unstructured":"Hou, A. J., Chen, L. C. & Chen, Y. Y. Navigating CAR-T cells through the solid-tumour microenvironment. Nat. Rev. Drug Discov. 20, 531\u2013550 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"901_CR67","doi-asserted-by":"publisher","DOI":"10.1126\/science.adl4793","volume":"386","author":"NR Reddy","year":"2024","unstructured":"Reddy, N. R. et al. Engineering synthetic suppressor T cells that execute locally targeted immunoprotective programs. Science 386, eadl4793 (2024).","journal-title":"Science"},{"key":"901_CR68","doi-asserted-by":"publisher","DOI":"10.1126\/science.adl4237","volume":"386","author":"MS Simic","year":"2024","unstructured":"Simic, M. S. et al. Programming tissue-sensing T cells that deliver therapies to the brain. Science 386, eadl4237 (2024).","journal-title":"Science"},{"key":"901_CR69","doi-asserted-by":"publisher","first-page":"189235","DOI":"10.1016\/j.bbcan.2024.189235","volume":"1880","author":"M Zheng","year":"2025","unstructured":"Zheng, M., Qu, J., Xiang, D. & Xing, L. Organoids in lung cancer brain metastasis: Foundational research, clinical translation, and prospective outlooks. Biochim Biophys. Acta Rev. Cancer 1880, 189235 (2025).","journal-title":"Biochim Biophys. Acta Rev. Cancer"},{"key":"901_CR70","volume":"3","author":"R Tonse","year":"2021","unstructured":"Tonse, R. et al. Systematic review and meta-analysis of PD-L1 expression discordance between primary tumor and lung cancer brain metastasis. Neurooncol Adv. 3, vdab166 (2021).","journal-title":"Neurooncol Adv."},{"key":"901_CR71","doi-asserted-by":"publisher","first-page":"e14002","DOI":"10.1200\/JCO.2024.42.16_suppl.e14002","volume":"42","author":"N Sadagopan","year":"2024","unstructured":"Sadagopan, N., Komlodi-Pasztor, E. & Veytsman, I. Breaking barriers: Real-world data on immunotherapy in non-small cell lung cancer with large brain metastases. J. Clin. Oncol. 42, e14002 (2024).","journal-title":"J. Clin. Oncol."},{"key":"901_CR72","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","volume":"8","author":"F Skoulidis","year":"2018","unstructured":"Skoulidis, F. et al. STK11\/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov. 8, 822\u2013835 (2018).","journal-title":"Cancer Discov."},{"key":"901_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00403-x","volume":"7","author":"C Barrera","year":"2023","unstructured":"Barrera, C. et al. Deep computational image analysis of immune cell niches reveals treatment-specific outcome associations in lung cancer. NPJ Precis Oncol. 7, 52 (2023).","journal-title":"NPJ Precis Oncol."},{"key":"901_CR74","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1093\/neuonc\/noad236","volume":"26","author":"AE Kim","year":"2024","unstructured":"Kim, A. E. et al. Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance. Neuro Oncol. 26, 965\u2013974 (2024).","journal-title":"Neuro Oncol."},{"key":"901_CR75","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-024-00779-4","volume":"24","author":"CY Liao","year":"2024","unstructured":"Liao, C. Y. et al. Personalized prediction of immunotherapy response in lung cancer patients using advanced radiomics and deep learning. Cancer Imaging 24, 129 (2024).","journal-title":"Cancer Imaging"},{"key":"901_CR76","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1158\/2159-8290.CD-20-0047","volume":"10","author":"Q Zhang","year":"2020","unstructured":"Zhang, Q. et al. Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. Cancer Discov. 10, 1842\u20131853 (2020).","journal-title":"Cancer Discov."},{"key":"901_CR77","doi-asserted-by":"publisher","first-page":"e534","DOI":"10.1016\/S1470-2045(15)00088-1","volume":"16","author":"H Okada","year":"2015","unstructured":"Okada, H. et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 16, e534\u2013e542 (2015).","journal-title":"Lancet Oncol."},{"key":"901_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-49639-4","volume":"13","author":"K Kim","year":"2023","unstructured":"Kim, K. et al. Genomic hypomethylation in cell-free DNA predicts responses to checkpoint blockade in lung and breast cancer. Sci. Rep. 13, 22482 (2023).","journal-title":"Sci. Rep."},{"key":"901_CR79","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41591-024-03286-y","volume":"31","author":"JA Zuccato","year":"2025","unstructured":"Zuccato, J. A. et al. Prediction of brain metastasis development with DNA methylation signatures. Nat. Med. 31, 116\u2013125 (2025).","journal-title":"Nat. Med."},{"key":"901_CR80","doi-asserted-by":"publisher","first-page":"S806","DOI":"10.1016\/j.annonc.2024.08.1315","volume":"35","author":"M van den Heuvel","year":"2024","unstructured":"van den Heuvel, M., van der Noort, V. & Ter Heine, R. 1258MO Low dose versus standard dose pembrolizumab for treatment of stage IV stage non-small cell lung carcinoma: Results of the pre-planned interim analysis of the NVALT-30 clinical trial. Ann. Oncol. 35, S806 (2024).","journal-title":"Ann. Oncol."},{"key":"901_CR81","doi-asserted-by":"publisher","first-page":"S871","DOI":"10.1016\/j.annonc.2024.08.1446","volume":"35","author":"ZW Xu","year":"2024","unstructured":"Xu, Z. W. et al. 1391TiP TACTC-2 trial: Efficacy of pembrolizumab +- chemotherapy first-line therapy in advanced non-small cell lung cancer patients with PD-L1 expression >=50 adjusting in accordance with CtDNA. Ann. Oncol. 35, S871 (2024).","journal-title":"Ann. Oncol."},{"key":"901_CR82","doi-asserted-by":"publisher","first-page":"S254","DOI":"10.1016\/j.annonc.2024.08.109","volume":"35","author":"F Wu","year":"2024","unstructured":"Wu, F. et al. 101P Circulating tumor DNA minimal residual disease predicts the risk of progression after long-term response to first-line immunotherapy in advanced NSCLC. Ann. Oncol. 35, S254 (2024).","journal-title":"Ann. Oncol."},{"key":"901_CR83","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.cllc.2024.10.013","volume":"26","author":"A Hsiao","year":"2025","unstructured":"Hsiao, A. et al. Brief Report: Methylation-Based ctDNA Serial Monitoring Correlates With Immunotherapy Response in NSCLC. Clin. Lung Cancer 26, 72\u201377 (2025).","journal-title":"Clin. Lung Cancer"},{"key":"901_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.bios.2025.117236","volume":"275","author":"Y Liu","year":"2025","unstructured":"Liu, Y. et al. A facile liquid biopsy assay for highly efficient CTCs capture and reagent-less monitoring of immune checkpoint PD-L1 expression on CTCs with non-small cell lung cancer patients. Biosens. Bioelectron. 275, 117236 (2025).","journal-title":"Biosens. Bioelectron."},{"key":"901_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21789-x","volume":"12","author":"C Rubio-Perez","year":"2021","unstructured":"Rubio-Perez, C. et al. Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment. Nat. Commun. 12, 1503 (2021).","journal-title":"Nat. Commun."},{"key":"901_CR86","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2023.2290790","volume":"13","author":"M Li","year":"2024","unstructured":"Li, M. et al. Cerebrospinal fluid immunological cytokines predict intracranial tumor response to immunotherapy in non-small cell lung cancer patients with brain metastases. Oncoimmunology 13, 2290790 (2024).","journal-title":"Oncoimmunology"},{"key":"901_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25860-5","volume":"12","author":"SM Prakadan","year":"2021","unstructured":"Prakadan, S. M. et al. Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases. Nat. Commun. 12, 5955 (2021).","journal-title":"Nat. Commun."},{"key":"901_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102807","volume":"130","author":"M Weller","year":"2024","unstructured":"Weller, M. et al. Central nervous system metastases in advanced non-small cell lung cancer: A review of the therapeutic landscape. Cancer Treat. Rev. 130, 102807 (2024).","journal-title":"Cancer Treat. Rev."},{"key":"901_CR89","doi-asserted-by":"publisher","first-page":"e23299","DOI":"10.1200\/JCO.2024.42.16_suppl.e23299","volume":"42","author":"P Sharma","year":"2024","unstructured":"Sharma, P. et al. Trends in survival in solid malignancies with synchronous brain metastases: A population-based study. J. Clin. Oncol. 42, e23299 (2024).","journal-title":"J. Clin. Oncol."},{"key":"901_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33365-y","volume":"13","author":"Q Zhang","year":"2022","unstructured":"Zhang, Q. et al. The spatial transcriptomic landscape of non-small cell lung cancer brain metastasis. Nat. Commun. 13, 5983 (2022).","journal-title":"Nat. Commun."},{"key":"901_CR91","doi-asserted-by":"publisher","first-page":"S1243","DOI":"10.1016\/j.annonc.2024.08.2295","volume":"35","author":"N Girard","year":"2024","unstructured":"Girard, N. et al. LBA53 Nivolumab (NIVO) plus relatlimab with platinum-doublet chemotherapy (PDCT) vs NIVO + PDCT as first-line (1L) treatment (tx) for stage IV or recurrent NSCLC: Results from the randomized phase II RELATIVITY-104 study. Ann. Oncol. 35, S1243\u2013S1244 (2024).","journal-title":"Ann. Oncol."},{"key":"901_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102684","volume":"9","author":"W Xu","year":"2024","unstructured":"Xu, W. et al. 105TiP Adebrelimab combined with famitinib in the treatment of PD-L1\u226550% advanced non-small cell lung cancer with brain metastases: A prospective, single-arm trial (BRAIN-AF01). ESMO Open 9, 102684 (2024).","journal-title":"ESMO Open"},{"key":"901_CR93","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(24)02722-3","volume":"405","author":"A Xiong","year":"2025","unstructured":"Xiong, A. et al. Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China. The Lancet. 405, 839\u2013849 (2025).","journal-title":"The Lancet."},{"key":"901_CR94","doi-asserted-by":"publisher","first-page":"S485","DOI":"10.1016\/j.annonc.2024.08.672","volume":"35","author":"H Zhao","year":"2024","unstructured":"Zhao, H. et al. 605O YL201, a novel B7H3-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors: Results from a first-in-human phase I study. Ann. Oncol. 35, S485 (2024).","journal-title":"Ann. Oncol."},{"key":"901_CR95","doi-asserted-by":"publisher","first-page":"S486","DOI":"10.1016\/j.annonc.2024.08.674","volume":"35","author":"M Oliva","year":"2024","unstructured":"Oliva, M. et al. 607O Interim results of a phase I study of SGN-PDL1V (PF-08046054) in patients with PDL1-expressing solid tumors. Ann. Oncol. 35, S486 (2024).","journal-title":"Ann. Oncol."},{"key":"901_CR96","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1016\/j.cllc.2020.02.015","volume":"21","author":"H Wang","year":"2020","unstructured":"Wang, H. et al. A Preliminary Study of Adoptive T-cell Transfer Therapy for Patients With Non-Small-cell Lung Adenocarcinoma With Brain Metastasis: A Case Report of 3 Patients. Clin. Lung Cancer 21, e270\u2013e273 (2020).","journal-title":"Clin. Lung Cancer"},{"key":"901_CR97","doi-asserted-by":"publisher","first-page":"S521","DOI":"10.1016\/j.annonc.2024.08.729","volume":"35","author":"MA Khattak","year":"2024","unstructured":"Khattak, M. A. et al. 663P First-in-human, phase I\/II, monotherapy, dose-escalation study of mRNA-4359, an mRNA-encoded PD-L1\/IDO1 antigen-specific therapy, in advanced\/refractory solid tumors. Ann. Oncol. 35, S521\u2013S522 (2024).","journal-title":"Ann. Oncol."},{"key":"901_CR98","first-page":"1","volume":"42","author":"EQ Lee","year":"2022","unstructured":"Lee, E. Q., Camidge, D. R. & Mehta, G. Extending Our Reach: Expanding Enrollment in Brain Metastases and Primary Brain Tumor Clinical Trials. Am. Soc. Clin. Oncol. Educ. Book 42, 1\u20139 (2022).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"901_CR99","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1016\/S1470-2045(17)30692-7","volume":"19","author":"BM Alexander","year":"2018","unstructured":"Alexander, B. M. et al. Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncol. 19, e33\u2013e42 (2018).","journal-title":"Lancet Oncol."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-00901-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-00901-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-00901-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T19:02:47Z","timestamp":1746558167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-00901-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":99,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["901"],"URL":"https:\/\/doi.org\/10.1038\/s41698-025-00901-0","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]},"assertion":[{"value":"17 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"130"}}